Development and validation of a baseline interpretable prognostic model for mortality risk stratification in myelodysplastic syndrome patients receiving hypomethylating agent therapy

Current Problems in Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles